Group 1 - SIGA Technologies, Inc. will host a webcast and conference call for a business update on August 1, 2024, at 4:30 P.M. ET, featuring CEO Diem Nguyen and CFO Daniel Luckshire [1] - The call will be accessible via the company's website and through specific dial-in numbers for domestic and international participants [2] - A replay of the call will be available for two weeks, along with an archived webcast on the company's website [3] Group 2 - SIGA is a commercial-stage pharmaceutical company focused on developing innovative medicines for infectious diseases, particularly orthopoxviruses [4] - The company's flagship product, TPOXX® (tecovirimat), is approved in the U.S. and Canada for smallpox treatment and authorized in Europe and the UK for smallpox, mpox, cowpox, and vaccinia complications [4]

The most recent trading session ended with Siga Technologies Inc. (SIGA) standing at $9.72, reflecting a +0.83% shift from the previouse trading day's closing. The stock exceeded the S&P 500, which registered a loss of 2.32% for the day. Elsewhere, the Dow lost 1.25%, while the tech-heavy Nasdaq lost 3.64%. The investment community will be closely monitoring the performance of Siga Technologies Inc. in its forthcoming earnings report. Investors should also take note of any recent adjustments to analyst esti ...

Core Points - SIGA Technologies, Inc. announced a procurement option exercised by the U.S. Department of Health and Human Services for approximately $113 million of oral TPOXX® treatment courses [1][5] - This order is part of ongoing efforts to enhance orthopoxvirus preparedness and ensure public health against various threats [5] Company Overview - SIGA is a commercial-stage pharmaceutical company focused on developing innovative medicines for infectious diseases, particularly orthopoxviruses [6] - The company's flagship product, TPOXX® (tecovirimat), is approved in the U.S. and Canada for smallpox treatment and authorized in Europe and the UK for smallpox, mpox, cowpox, and vaccinia complications [6]

The most recent trading session ended with Siga Technologies Inc. (SIGA) standing at $9.06, reflecting a +0.55% shift from the previouse trading day's closing. The stock's performance was ahead of the S&P 500's daily loss of 0.78%. Meanwhile, the Dow lost 1.29%, and the Nasdaq, a tech-heavy index, lost 0.7%. Prior to today's trading, shares of the company had gained 42.56% over the past month. This has outpaced the Medical sector's gain of 2.23% and the S&P 500's gain of 2.14% in that time. The investment c ...

The most recent trading session ended with Siga Technologies Inc. (SIGA) standing at $8.69, reflecting a +1.88% shift from the previouse trading day's closing. The stock exceeded the S&P 500, which registered a loss of 0.88% for the day. On the other hand, the Dow registered a gain of 0.08%, and the technology-centric Nasdaq decreased by 1.95%. Investors will be eagerly watching for the performance of Siga Technologies Inc. in its upcoming earnings disclosure. It is also important to note the recent changes ...

Prior to today's trading, shares of the company had gained 0.78% over the past month. This has outpaced the Medical sector's loss of 0.44% and lagged the S&P 500's gain of 4.08% in that time. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $1.18 per share and revenue of $177.56 million, indicating changes of +24.21% and +26.9%, respectively, compared to the previous year. Based on our research, we believe these estimate revisions are directly related to near-team stock moves. T ...

A spokesperson from the Ministry of Health, Brunei Darussalam said, "We are pleased to support the ASEANwide effort to prepare for and respond to public health events. Ensuring adequate supply and access to countermeasures is a vital part of preparedness and this initiative by the region strengthens our collective health security against the Mpox threat." ASEAN, established in August 1967, is comprised of Brunei Darussalam, Cambodia, Indonesia, Lao PDR, Malaysia, Myanmar, Philippines, Singapore, Thailand, a ...

Company Overview - SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on health security, including countermeasures for biological threats and therapies for infectious diseases [4] - The company's lead product is TPOXX (tecovirimat), an antiviral drug for treating smallpox [4] Recent Developments - SIGA announced an agreement to expand access to TPOXX for ASEAN member states, coordinated with Meridian Medical Technologies [1][2] - The agreement reflects the use of ASEAN funds to support public health preparedness against potential health events, particularly the Mpox threat [2] Strategic Importance - The ASEAN region, with a population exceeding 600 million and a GDP of $3.6 trillion, represents a significant market for SIGA [2] - This contract establishes a footprint in a densely populated area and lays the groundwork for future activities in Asia [2] Product Information - TPOXX is a novel small-molecule drug approved by the FDA for smallpox treatment in 2018, with an intravenous formulation approved in 2022 [5] - The drug has also received approvals from the European Medicines Agency and the UK's Medicines and Healthcare Products Regulatory Agency for multiple indications, including Mpox and cowpox [5] Market Context - Orthopoxviruses, including smallpox and Mpox, pose a risk to global health security, necessitating effective antiviral solutions [6][7] - Recent Mpox outbreaks in various regions highlight the importance of preparedness and response strategies [6]

SIGA Technologies, Inc. (NASDAQ:SIGA) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Diem Nguyen - Chief Executive Officer Dan Luckshire - Chief Financial Officer Conference Call Participants Soo Romanoff - Edison Group Brian Adams - Carter, Terry Operator Welcome to the SIGA Business Update Call. Before we turn the call over to SIGA management, please note that any forward-looking statements made during this call are based on management’s current expectations and observations ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2024 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ________ to ___________ (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 31 East 62nd Street ...